Group 1: Company Overview - The company, Shandong Boyuan Pharmaceutical Chemical Co., Ltd., focuses on fine chemicals, with iodides being the primary revenue contributor [2]. - The current production capacity for iodide products is 4,100 tons/year, with an additional 4,000 tons/year in trial production [2]. Group 2: Product Details - The main categories of fine chemicals include iodides, luminescent materials, hexamethyldisilazane, and precious metal catalysts, with iodides leading in revenue [2]. - The inorganic iodides include potassium iodide, potassium iodate, sodium iodide, hydriodic acid, and cuprous iodide, while organic iodides consist of trimethyl iodide and iodomethane [2]. Group 3: Market Outlook - The market for inorganic iodides is expected to grow due to increasing demand in the pharmaceutical sector, driven by rising healthcare spending and aging populations [3]. - The demand for iodinated contrast agents in medical imaging (CT and MRI) is projected to rise, contributing to the expansion of the domestic contrast agent market [3]. - In the electronics manufacturing sector, the shift of global panel production to China is increasing the domestic market share of polarizer manufacturers, with iodinated polarizers holding an 80%-90% market share [3]. Group 4: Shareholder Information - A total of 19,630,000 shares will be released from lock-up on December 11, 2025, with no current plans for shareholder reduction reported [3]. - The company will disclose any future reduction plans in accordance with legal requirements [3]. Group 5: Raw Material Sourcing - The company sources iodine through a dual-channel model of "resource recycling and recovery + import supplementation" [5].
博苑股份(301617) - 2025年12月9日投资者关系活动记录表